Reporter brief
Pilot Study of the Evaluation of Intravitreal Sirolimus in the Treatment of Bilateral Geographic Atrophy Associated With Age-Related Macular Degeneration
What happened
Trial registry update: COMPLETED. Results are posted in the registry; assessment pending.
Why it matters
Assessment pending; this report does not establish a change in evidence.
What it does NOT prove
- This pilot study has not reported its results, making it impossible to determine whether sirolimus was actually safe or effective for GA.
- Without a control group or comparison arm, any safety or efficacy findings would reflect only the treated population and could not determine whether sirolimus caused observed changes.
- The study design and abstract do not indicate whether vision preservation or other clinical outcomes were measured or how they were assessed.
Study design and sample
Other; Human.
People at least 56 years of age with geographic atrophy related to age-related macular degeneration in both eyes
- Design
- Other
- Sample
- —
- Journal
- National Eye Institute (NEI)
- Published
- Jul 7, 2021
Effect size
Not recorded.
Caveats
- Assessment: Unassessed.
- Only the source material recorded on this evidence page was assessed.
Conflicts and funding
Not recorded.
Previous evidence
See the Rapamycin timeline and recorded assessment for prior evidence.
Primary source
Cancel Death charts and briefs may be reproduced editorially with attribution to CancelDeath.com. This brief is generated from the primary recorded source facts and assessment. Its review status is shown below; verify quotations against the paper before publication.